AI-generated · cited to primary sources · not investment advice
Health.Global (539787) Feb 2026 Filing Analysis
Does management do what it says?
International business is growing, but remains below the stated 6–8% revenue ambition. The disclosed international revenue share is 5% for 9MFY26; the Q3 highlights separately describe Africa as approximately 2% of revenue. (2 in progress across 2 tracked commitments)
“Currently, it is about 3.5%, Rajat, and our endeavour is to take it to about 7% in the next four years.”
See the full cited Management analysis of Health.Global
How durable is the business?
Management described a higher contribution from medical oncology, including immunotherapy and CAR-T therapies, particularly in Bengaluru. Its increasing presence was associated with a lower gross margin, partly because of pharmacy costs, but management said the added activity supports EBITDA through better use of hospital capacity. The call gives no specialty revenue share, so the later 39% share cannot be compared quantitatively. (1 expanding)
“the case mix continued to improve, supported by a higher contribution from high-end medical oncology work, including immunotherapy and CAR-T cell therapies, particularly at the Centre of Excellence in Bangalore.”
See the full cited Business Model analysis of Health.Global
Where does growth come from?
The transcript does not report international-patient revenue or its growth for Q3 FY26. It does give a forward target for medical tourism: increase its share from about 3.5% currently to about 7% within four years. This is a stated growth ambition, not a quarterly revenue series. (1 new trend across 1 signal)
“Currently, it is about 3.5%... our endeavour is to take it to about 7% in the next four years.”
See the full cited Future Growth analysis of Health.Global
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.